GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Henan Taloph Pharmaceutical Stock Co Ltd (SHSE:600222) » Definitions » Piotroski F-Score

Henan Taloph Pharmaceutical Stock Co (SHSE:600222) Piotroski F-Score : 7 (As of Jun. 16, 2024)


View and export this data going back to 1999. Start your Free Trial

What is Henan Taloph Pharmaceutical Stock Co Piotroski F-Score?

Good Sign:

Piotroski F-Score is 7, indicates a very healthy situation.

The zones of discrimination were as such:

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Henan Taloph Pharmaceutical Stock Co has an F-score of 7. It is a good or high score, which usually indicates a very healthy situation.

The historical rank and industry rank for Henan Taloph Pharmaceutical Stock Co's Piotroski F-Score or its related term are showing as below:

SHSE:600222' s Piotroski F-Score Range Over the Past 10 Years
Min: 1   Med: 5   Max: 9
Current: 7

During the past 13 years, the highest Piotroski F-Score of Henan Taloph Pharmaceutical Stock Co was 9. The lowest was 1. And the median was 5.


Henan Taloph Pharmaceutical Stock Co Piotroski F-Score Historical Data

The historical data trend for Henan Taloph Pharmaceutical Stock Co's Piotroski F-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Henan Taloph Pharmaceutical Stock Co Piotroski F-Score Chart

Henan Taloph Pharmaceutical Stock Co Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Piotroski F-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only 7.00 6.00 5.00 1.00 9.00

Henan Taloph Pharmaceutical Stock Co Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Piotroski F-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3.00 1.00 5.00 9.00 7.00

Competitive Comparison of Henan Taloph Pharmaceutical Stock Co's Piotroski F-Score

For the Drug Manufacturers - Specialty & Generic subindustry, Henan Taloph Pharmaceutical Stock Co's Piotroski F-Score, along with its competitors' market caps and Piotroski F-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Henan Taloph Pharmaceutical Stock Co's Piotroski F-Score Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Henan Taloph Pharmaceutical Stock Co's Piotroski F-Score distribution charts can be found below:

* The bar in red indicates where Henan Taloph Pharmaceutical Stock Co's Piotroski F-Score falls into.


How is the Piotroski F-Score calculated?

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Mar24) TTM:Last Year (Mar23) TTM:
Net Income was -42.014 + 21.405 + 60.483 + 21.259 = ¥61 Mil.
Cash Flow from Operations was 4.267 + 35.312 + 96.427 + -115.824 = ¥20 Mil.
Revenue was 433.592 + 448.96 + 627.039 + 499.112 = ¥2,009 Mil.
Gross Profit was 90.19 + 121.271 + 199.783 + 136.499 = ¥548 Mil.
Average Total Assets from the begining of this year (Mar23)
to the end of this year (Mar24) was
(3572.513 + 3395.367 + 3339.323 + 3576.855 + 3652.922) / 5 = ¥3507.396 Mil.
Total Assets at the begining of this year (Mar23) was ¥3,573 Mil.
Long-Term Debt & Capital Lease Obligation was ¥185 Mil.
Total Current Assets was ¥2,070 Mil.
Total Current Liabilities was ¥1,736 Mil.
Net Income was -27.762 + -31.446 + -15.326 + 3.683 = ¥-71 Mil.

Revenue was 441.394 + 433.568 + 663.449 + 560.318 = ¥2,099 Mil.
Gross Profit was 82.109 + 88.671 + 172.272 + 153.478 = ¥497 Mil.
Average Total Assets from the begining of last year (Mar22)
to the end of last year (Mar23) was
(3789.529 + 3532.867 + 3541.531 + 3606.6 + 3572.513) / 5 = ¥3608.608 Mil.
Total Assets at the begining of last year (Mar22) was ¥3,790 Mil.
Long-Term Debt & Capital Lease Obligation was ¥44 Mil.
Total Current Assets was ¥1,983 Mil.
Total Current Liabilities was ¥1,907 Mil.

*Note: If the latest quarterly/semi-annual/annual total assets data is 0, then we will use previous quarterly/semi-annual/annual data for all the items in the balance sheet.

Profitability

Question 1. Return on Assets (ROA)

Net income before extraordinary items for the year divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Henan Taloph Pharmaceutical Stock Co's current Net Income (TTM) was 61. ==> Positive ==> Score 1.

Question 2. Cash Flow Return on Assets (CFROA)

Net cash flow from operating activities (operating cash flow) divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Henan Taloph Pharmaceutical Stock Co's current Cash Flow from Operations (TTM) was 20. ==> Positive ==> Score 1.

Question 3. Change in Return on Assets

Compare this year's return on assets (1) to last year's return on assets.

Score 1 if it's higher, 0 if it's lower.

ROA (This Year)=Net Income/Total Assets (Mar23)
=61.133/3572.513
=0.01711204

ROA (Last Year)=Net Income/Total Assets (Mar22)
=-70.851/3789.529
=-0.01869652

Henan Taloph Pharmaceutical Stock Co's return on assets of this year was 0.01711204. Henan Taloph Pharmaceutical Stock Co's return on assets of last year was -0.01869652. ==> This year is higher. ==> Score 1.

Question 4. Quality of Earnings (Accrual)

Compare Cash flow return on assets (2) to return on assets (1)

Score 1 if CFROA > ROA, 0 if CFROA <= ROA.

Henan Taloph Pharmaceutical Stock Co's current Net Income (TTM) was 61. Henan Taloph Pharmaceutical Stock Co's current Cash Flow from Operations (TTM) was 20. ==> 20 <= 61 ==> CFROA <= ROA ==> Score 0.

Funding

Question 5. Change in Gearing or Leverage

Compare this year's gearing (long-term debt divided by average total assets) to last year's gearing.

Score 0 if this year's gearing is higher, 1 otherwise.

Gearing (This Year: Mar24)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Mar23 to Mar24
=184.64/3507.396
=0.05264304

Gearing (Last Year: Mar23)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Mar22 to Mar23
=44.04/3608.608
=0.01220415

Henan Taloph Pharmaceutical Stock Co's gearing of this year was 0.05264304. Henan Taloph Pharmaceutical Stock Co's gearing of last year was 0.01220415. ==> Last year is lower than this year ==> Score 0.

Question 6. Change in Working Capital (Liquidity)

Compare this year's current ratio (current assets divided by current liabilities) to last year's current ratio.

Score 1 if this year's current ratio is higher, 0 if it's lower

Current Ratio (This Year: Mar24)=Total Current Assets/Total Current Liabilities
=2070.382/1735.561
=1.19291802

Current Ratio (Last Year: Mar23)=Total Current Assets/Total Current Liabilities
=1982.901/1907.173
=1.03970694

Henan Taloph Pharmaceutical Stock Co's current ratio of this year was 1.19291802. Henan Taloph Pharmaceutical Stock Co's current ratio of last year was 1.03970694. ==> This year's current ratio is higher. ==> Score 1.

Question 7. Change in Shares in Issue

Compare the number of shares in issue this year, to the number in issue last year.

Score 0 if there is larger number of shares in issue this year, 1 otherwise.

Henan Taloph Pharmaceutical Stock Co's number of shares in issue this year was 557.97. Henan Taloph Pharmaceutical Stock Co's number of shares in issue last year was 566.549. ==> There is smaller number of shares in issue this year, or the same. ==> Score 1.

Efficiency

Question 8. Change in Gross Margin

Compare this year's gross margin (Gross Profit divided by sales) to last year's.

Score 1 if this year's gross margin is higher, 0 if it's lower.

Gross Margin (This Year: TTM)=Gross Profit/Revenue
=547.743/2008.703
=0.27268491

Gross Margin (Last Year: TTM)=Gross Profit/Revenue
=496.53/2098.729
=0.23658605

Henan Taloph Pharmaceutical Stock Co's gross margin of this year was 0.27268491. Henan Taloph Pharmaceutical Stock Co's gross margin of last year was 0.23658605. ==> This year's gross margin is higher. ==> Score 1.

Question 9. Change in asset turnover

Compare this year's asset turnover (total sales for the year divided by total assets at the beginning of the year) to last year's asset turnover ratio.

Score 1 if this year's asset turnover ratio is higher, 0 if it's lower

Asset Turnover (This Year)=Revenue/Total Assets at the Beginning of This Year (Mar23)
=2008.703/3572.513
=0.56226611

Asset Turnover (Last Year)=Revenue/Total Assets at the Beginning of Last Year (Mar22)
=2098.729/3789.529
=0.55382318

Henan Taloph Pharmaceutical Stock Co's asset turnover of this year was 0.56226611. Henan Taloph Pharmaceutical Stock Co's asset turnover of last year was 0.55382318. ==> This year's asset turnover is higher. ==> Score 1.

Evaluation

Piotroski F-Score= Que. 1+ Que. 2+ Que. 3+Que. 4+Que. 5+Que. 6+Que. 7+Que. 8+Que. 9
=1+1+1+0+0+1+1+1+1
=7

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Henan Taloph Pharmaceutical Stock Co has an F-score of 7. It is a good or high score, which usually indicates a very healthy situation.

Henan Taloph Pharmaceutical Stock Co  (SHSE:600222) Piotroski F-Score Explanation

The developer of the system is Joseph D. Piotroski is relatively unknown accounting professor who shuns publicity and rarely gives interviews.

He graduated from the University of Illinois with a B.S. in accounting in 1989, received an M.B.A. from Indiana University in 1994. Five years later, in 1999, after earning a Ph.D. in accounting from the University of Michigan, he became an associate professor of accounting at the University of Chicago.

In 2000, he wrote a research paper called "Value Investing: The Use of Historical Financial Statement Information to Separate Winners from Losers" (pdf).

He wanted to see if he can develop a system (using a simple nine-point scoring system) that can increase the returns of a strategy of investing in low price to book (referred to in the paper as high book to market) value companies.

What he found was something that exceeded his most optimistic expectations.

Buying only those companies that scored highest (8 or 9) on his nine-point scale, or F-Score as he called it, over the 20 year period from 1976 to 1996 led to an average out-performance over the market of 13.4%.

Even more impressive were the results of a strategy of investing in the highest F-Score companies (8 or 9) and shorting companies with the lowest F-Score (0 or 1).

Over the same period from 1976 to 1996 (20 years) this strategy led to an average yearly return of 23%, substantially outperforming the average S&P 500 index return of 15.83% over the same period.


Henan Taloph Pharmaceutical Stock Co Piotroski F-Score Related Terms

Thank you for viewing the detailed overview of Henan Taloph Pharmaceutical Stock Co's Piotroski F-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


Henan Taloph Pharmaceutical Stock Co (SHSE:600222) Business Description

Traded in Other Exchanges
N/A
Address
No. 8, Jinsuo Road, High-tech Industrial Development Zone, Henan Province, Zhengzhou, CHN, 450001
Henan Taloph Pharmaceutical Stock Co Ltd is a Chinese company engaged in the manufacture of Western and Chinese medicine products, including oral liquids, tablets, capsules, and bulk drugs. Geographically, the business activities are functioned through China region.
Executives
Zhao Qing Xin Director

Henan Taloph Pharmaceutical Stock Co (SHSE:600222) Headlines

No Headlines